

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CSPC PHARMACEUTICAL GROUP LIMITED

石藥集團有限公司

(Incorporated in Hong Kong under the Companies Ordinance)

(Stock code: 1093)

VOLUNTARY ANNOUNCEMENT

CLARIFICATION OF ARTICLES

This announcement is published on a voluntary basis by CSPC Pharmaceutical Group Limited (the “Company”, together with its subsidiaries, the “Group”).

The board of directors of the Company (the “Board”) notices that some articles were recently published on certain websites (the “Articles”) which reported that (1) 石藥集團河北永豐藥業有限公司 (CSPC Hebei Yongfeng Pharmaceutical Co., Ltd.*) (“Hebei Yongfeng”) was involved in improper operation of its traditional Chinese medicines business and non-compliance of certain laws and regulations in the People’s Republic of China and the Certificate of Good Manufacturing Practices for Medicinal Products issued to Hebei Yongfeng was revoked and (2) Hebei Yongfeng is a subsidiary of the Company.

The Company wishes to clarify that the Articles were inaccurate. Hebei Yongfeng is not a subsidiary of the Company or a company within the Group.

* For identification purpose only

By Order of the Board
CSPC Pharmaceutical Group Limited
Cai Dongchen
Chairman

Hong Kong, 20 April 2016

As at the date of this announcement, the Board comprises Mr. CAI Dongchen, Mr. CHAK Kin Man, Mr. PAN Weidong, Mr. WANG Shunlong, Mr. WANG Huaiyu, Mr. LU Jianmin, Mr. WANG Zhenguo, Mr. WANG Jinxu and Mr. LU Hua as executive directors; Mr. LEE Ka Sze, Carmelo as non-executive director; and Mr. CHAN Siu Keung, Leonard, Mr. WANG Bo, Mr. LO Yuk Lam and Mr. YU Jinming as independent non-executive directors.